Tuesday, March 2, 2021

Janus kinase inhibition in the Aicardi-Goutières syndrome

Vanderver A, Adang L, Gavazzi F, McDonald K, Helman G, Frank DB, Jaffe N, Yum SW, Collins A, Keller SR, Lebon P, Meritet JF, Rhee J, Takanohashi A, Armangue T, Ulrick N, Sherbini O, Koh J, Peer K, Besnier C, Scher C, Boyle K, Dubbs H, Kramer-Golinkoff J, Pizzino A, Woidill S, Shults J. Janus Kinase Inhibition in the Aicardi-Goutières Syndrome. N Engl J Med. 2020 Sep 3;383(10):986-989. doi: 10.1056/NEJMc2001362. PMID: 32877590; PMCID: PMC7495410. 

The Aicardi–Goutières syndrome is a genetic interferonopathy that is associated with severe disability and death. Most children with this syndrome are unable to walk or talk and have multisystemic complications, including skin inflammation (figure in article). Janus kinase (JAK) inhibitors may be effective in blocking interferon activation in patients with the Aicardi–Goutières syndrome. 

We conducted an open-label study of a single-center, expanded-access program (ClinicalTrials.gov numbers, NCT01724580. opens in new tab and NCT03047369. opens in new tab; see the protocol, available with the full text of this letter at NEJM.org) involving 35 patients with genetically confirmed Aicardi–Goutières syndrome. The patients received baricitinib, an oral JAK1 and JAK2 inhibitor. Eli Lilly provided the medication for the study and provided support for safety monitoring. 

The median age at the onset of symptoms was 6.0 months, and the median age at the initiation of baricitinib was 2.9 years (range, 0.2 to 21.8). The patients participated in the study for a minimum of 12.0 months (range, 11.8 to 43.8). The dose of baricitinib, which ranged from 0.1 to 0.6 mg per kilogram of body weight per day, administered in 2 to 4 dosing increments per day, was determined according to the patient’s renal function, age, and symptoms.

JAK inhibitors are associated with infection, anemia, lymphopenia, and thrombosis. Two patients died during the study: one who had been receiving glucocorticoids for a decade, including a 7-year period before the study, had Aicardi–Goutières syndrome–related multisystem organ failure with an opportunistic infection, and the other had Aicardi–Goutières syndrome–related pulmonary hypertension with thrombotic microangiopathy. Clinical variables were measured with laboratory tests and graded according to Common Terminology Criteria for Adverse Events, version 5.0, in which grades range from 1 to 5, with higher grades indicating more severe adverse events. Among these variables, only thrombocytosis increased in severity during the study (mean change in grade from baseline, 0.30; 95% confidence interval [CI], 0.04 to 0.60). 

A biomarker for interferon signaling, the interferon-signaling gene-expression score, indicated a response to treatment (figure in article). This score is calculated from the expression of six interferon-signaling genes normalized to housekeeping genes. The six-gene interferon signature is the sum of the median z scores of these genes. The interferon signature is positive (i.e., type 1 interferon signaling is high) if it is at least 1.96 (>98th percentile) on a one-tailed test (see the Supplemental Methods section in the Supplementary Appendix, available at NEJM.org). 

The parents of the patients used diaries to record the children’s Aicardi–Goutières syndrome–related symptoms, including neurologic disability, crying, sleep disturbances, irritability, seizures, fever, and skin inflammation of the trunk, arms, and legs (see the Supplemental Methods section and Table S5 in the Supplementary Appendix in article). The diary score included a total of 24 possible points, assigned every day, with daily scores averaged across the time period before each visit (1 month after the initiation of baricitinib and then every 3 months). Scores obtained during the study ranged from 0 to 10.6, with higher scores indicating more severe symptoms. The skin subscore included a total of 6 possible points, with higher scores indicating more severe symptoms. The overall diary scores improved within 1 month after the initiation of therapy (mean change in overall score, −0.7 diary points; 95% CI, −1.2 to −0.2) and were sustained (mean change in overall score, −1.4; 95% CI, −2.2 to −0.6) (figures in article). The percentage of patients with a lower (improved) skin subscore of only 0 or 1 increased from 66% (23 of 35 patients) to 83% (29 of 35 patients) from the baseline visit to the final visit (difference, 17 percentage points; 95% CI, 2 to 32). 

We evaluated the patients’ developmental histories from disease onset (median age since disease onset, 16.5 months; interquartile range, 7.4 to 41.5) to the clinical data cutoff date (figure in article). We extracted information on key milestones, including head control, sitting, rolling, assisted and independent ambulation, grasp, smiling, babbling, and the use of single words and word combinations. Before treatment, 26 of the 35 patients had stable or declining neurologic function, and 9 of the 35 patients gained one or two skills after disease onset. During the study, 20 patients met new milestones, and 12 patients gained two to seven new skills. This improvement was noted by 3 months (mean change in the number of milestones, 0.5; 95% CI, 0.2 to 0.9) and persisted (mean change, 1.3; 95% CI, 0.6 to 1.9). One patient lost skills during an acute illness while participating in the study. Children in a higher daily dose category of baricitinib met more milestones (mean increase, 1.3 milestones; 95% CI, 0.6 to 1.9) than those in a lower daily dose category according to weight-based calculations (figure in article). 

The primary risks associated with baricitinib among patients with the Aicardi–Goutières syndrome were thrombocytosis, leukopenia, and infection (see Section 4.1.2 in the Supplementary Appendix in article). Patients who are receiving baricitinib should be monitored closely, especially those with underlying thrombotic risk factors or those who are receiving systemic glucocorticoids or immunosuppressive regimens. Because this study drew from an international population, we anticipate that our findings will be generalizable. The measurement of neurologic improvement is complex, but our data suggest improvement in neurologic function, even in patients with severe and long-standing disease.

No comments:

Post a Comment